Header Logo

Nirav Shah

TitleGraduate Student
InstitutionBaylor College of Medicine
DepartmentGenetics & Genomics
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shah NN, Tan T, Honorato-Mauer J, Lin YS, Maihofer AX, Zai CC, PGC-PTSD ancestry working group, Santoro M, Nievergelt CM, Atkinson EG, Shah NN, Tan T, Honorato-Mauer J, Lin YS, Maihofer AX, Zai CC, PGC-PTSD ancestry working group , Santoro M, Nievergelt CM, Atkinson EG. Tractor workflow: a scalable Nextflow framework for local ancestry-aware genome-wide association studies. Bioinformatics. 2026 May 03; 42(5). PMID: 41838407; PMCID: PMC13197121.
      Citations:    Fields:    Translation:Humans
    2. Stollenwerk TM, Barnett ME, Steineck AS, Shah NN, Knight JM. Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion. Brain Behav Immun Health. 2026 Jul; 54:101251. PMID: 42112476; PMCID: PMC13156647.
      Citations:    
    3. Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR. Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2026 Apr 28; 10(8):2698-2710. PMID: 41632629; PMCID: PMC13101680.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarf? L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14; 10(7):2441-2451. PMID: 41544219; PMCID: PMC13083716.
      Citations:    Fields:    Translation:Humans
    5. Gourbault LJ, Whitham R, Womersley A, Jones E, Christie A, Duggleby L, Atherton WG, CURFFED Collaborative, Doughty B, Smith I, Hassan AR, Levitt W, Davies A, Carpenter C, Saltanat S, Buddhdev P, Lennox-Warburton H, Donnelly E, Kim K, Farooq J, Dean CS, Edwards C, Mahmoud M, Stone A, Oyekan A, Jalgaonkar A, To C, Hunt A, Garner M, Campion A, Sison M, Irby S, Price M, Sharoff L, Worley R, Tahir H, Bircher A, Modi N, Theobald E, Genena A, Carter D, Milnes L, Roberts T, Vasudev A, Green D, Boucher A, Caruana E, Khokhar O, Kumar P, Rahman H, Seewoonarain S, Thumbadoo R, Forster S, Vadivelu R, Bagshaw L, Varghese B, Thalanki S, Franco AC, Hamid L, Liew I, Robinson J, Gurung I, Figg P, Moverley R, Neal-Smith G, Barot K, Oo TP, Hanger J, Larsen M, Jones A, Lougher L, Flintoft-Burt M, Dellis S, Kamal T, Bajaj S, Chema K, Lebe M, Bhandari G, Jeans E, James K, Barrow T, Fernandez L, Razemba T, Hawkins R, Anderson K, Tillotson L, Thomas W, Burden E, Kadambande S, Ibrahim IK, O'Boyle M, McCormack L, O'Donnell J, Baird E, MacDonald F, Aithie J, Robinson P, Esland J, Keightley A, Jain A, Thakker D, Nayak M, Caamina L, Barrow T, Discalicau D, Lockton Z, Burgan A, Morris G, Bansal R, Sinha M, Mostafa O, Ishaq U, Elmorsy A, Thomas A, Ross P, Theivendran K, Khaleeq T, Lindisfarne E, Gangadharan R, Thiruchandran G, Youssef K, Tober A, Shah N, Varasteh A, Bajracharya A, Lashin A, Mifsud M, Lloyd T, Kirk C, Ball T, Sheen J, Kapoor S, Jones IT, Donnachie D, Clamp K, Westacott D, Miller J, Hedge E, Gomindes A, Amour L, Ibrahim J, Dwyer J, Bickley M, Fulcher E, Chourasia AK, Hosny S, Hashem M, Dutta A, Leong D, Fergurson K, Haddock A, Malik M, Varasteh A, Cruz L, Jenkins L, East J, Oxley C. The Children's Urgent Reduction of Forearm Fractures in the Emergency Department (CURFFED) project : a national prospective trainee-led collaborative audit of practice. Bone Jt Open. 2026 Apr 11; 7(4):531-539. PMID: 41962925; PMCID: PMC13068486.
      Citations:    
    6. Pham DL, Kalluri M, Weaver C, Hsu A, Gillette A, Zhao W, Kearl T, Hematti P, Shah NN, Skala MC. Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response. Mol Ther Adv. 2026 Jun 11; 34(2):201704. PMID: 42137595; PMCID: PMC13148902.
      Citations:    
    7. Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens D, Romancik J, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Herr MM, Davis J, Jesme C, Pelcovits AR, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover N, Karmali R. Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. Blood Adv. 2026 Feb 10; 10(3):725-732. PMID: 41201962.
      Citations:    Fields:    Translation:Humans
    8. Coombs CC, Woyach JA, Brown JR, Ghia P, Roeker LE, Patel K, Eyre TA, Tam CS, Seymour JF, Shah NN, Flinn I, Cheah CY, Ma S, Rhodes JM, Izutsu K, Jurczak W, Wierda WG, Hess LM, Bhandari NR, Loubert A, Abada PB, Lamanna N. Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec; 41(12):2323-2338. PMID: 41612863.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Pulick E, Carey KA, Qyli T, Oguss MK, Picart JK, Penumalee L, Nezirova LK, Tully ST, Gilbert ER, Shah NS, Ravichandran U, Afshar M, Edelson DP, Mintz Y, Churpek MM. Treatment Recommendations for Clinical Deterioration on the Wards: Development and Validation of Machine Learning Models. JMIR AI. 2026 Jan 16; 5:e81642. PMID: 41544252; PMCID: PMC12810948.
      Citations:    
    10. Aughey E, Shah NN, Hillard CJ, Rentscher KE, Hamadani M, Longo W, Devata S, Knight JM, Cusatis R. Financial Toxicity in a Phase I/II Trial of LV20.19 CAR-T Cell for B-cell Malignancies: A Longitudinal, Qualitative Study. Transplant Cell Ther. 2026 May; 32(5):621.e1-621.e11. PMID: 41485560; PMCID: PMC12952239.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG. Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. Blood. 2026 Jan 01; 147(1):24-34. PMID: 41055698; PMCID: PMC12824664.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025 Dec 09; 9(23):5954-5964. PMID: 40845254; PMCID: PMC12686794.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. Pham DL, Kalluri M, Weaver C, Hsu A, Gillette A, Zhao W, Kearl T, Hematti P, Shah N, Skala MC. Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response. bioRxiv. 2025 Nov 16. PMID: 41292840; PMCID: PMC12642466.
      Citations:    
    14. Locke FL, Nikiforow S, Frigault MJ, Maloney DG, Davila M, Miklos DB, Lin Y, Vong J, Shah NN, Neelapu SS, Welch J, Ng E, Jacobson C, Maus MV. Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies. Transplant Cell Ther. 2025 Nov 07. PMID: 41207382.
      Citations:    Fields:    
    15. Annunzio K, Shah NN. Sequencing CAR-Ts in Relapsed DLBCL: Is More Always Better? Transplant Cell Ther. 2025 Nov; 31(11):849-850. PMID: 41176372.
      Citations:    Fields:    
    16. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>. Transplant Cell Ther. 2025 Oct 30. PMID: 41067707; PMCID: PMC12677140.
      Citations:    Fields:    
    17. Karczewski KJ, Gupta R, Kanai M, Lu W, Tsuo K, Wang Y, Walters RK, Turley P, Callier S, Shah NN, Baya N, Palmer DS, Goldstein JI, Sarma G, Solomonson M, Cheng N, Bryant S, Churchhouse C, Cusick CM, Poterba T, Compitello J, King D, Zhou W, Seed C, Finucane HK, Daly MJ, Neale BM, Atkinson EG, Martin AR. Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects. Nat Genet. 2025 Oct; 57(10):2408-2417. PMID: 40968291; PMCID: PMC13192283.
      Citations: 28     Fields:    Translation:Humans
    18. Shah NN, Tan T, Honorato-Mauer J, Lin YS, Maihofer AX, Zai CC, PGC-PTSD ancestry working group, Santoro M, Nievergelt CM, Atkinson EG. Tractor Workflow Pipeline: A Scalable Nextflow Framework for Local Ancestry-Aware Genome-Wide Association Studies. bioRxiv. 2025 Sep 04. PMID: 40950129; PMCID: PMC12424779.
      Citations:    
    19. Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Ruiz-Unger J, Shah NS, Mehta M, Cardona OQ, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S, Accelerating COVID-19 Therapeutic Interventions and Vaccines?6 Study Group and Investigators. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1092-1101. PMID: 40658388; PMCID: PMC12261116.
      Citations: 4     Fields:    Translation:HumansCells
    20. Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Shah NS, Mehta M, Quintero Cardona O, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial. medRxiv. 2025 Aug 12. PMID: 40832427; PMCID: PMC12363699.
      Citations:    
    21. Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec; 31(12):1000.e1-1000.e11. PMID: 40754223; PMCID: PMC12718520.
      Citations: 1     Fields:    Translation:Humans
    22. Tan T, Vergara-Lope A, Mart?nez-Maga?a JJ, Shah NN, Yuan K, Berumen J, Alegre-D?az J, Kuri-Morales P, Tapia-Conyer R, Gelenter J, Montalvo-Ortiz JL, Zhou W, Torres JM, Atkinson EG. Extending Genome-Wide Association Studies to admixed cohorts with high degrees of relatedness. medRxiv. 2025 Jun 09. PMID: 40585113; PMCID: PMC12204420.
      Citations:    
    23. Abess AT, Shah NJ, Whitlock EL, Schroeck H, Ron D, Rozek SB, Martinez-Camblor P, Donovan AL, Schenning KJ, Deiner SG, MPOG Collaborators. Brain Health Screening in Older Surgical Patients: A Multicenter, Retrospective, Observational Analysis and Survey. Anesth Analg. 2025 Nov 01; 141(5):1097-1106. PMID: 40378079.
      Citations:    Fields:    Translation:HumansPHPublic Health
    24. Benn L, Shah N, McKinney A, Min L, Aleem I, Luzum M, Vlisides PE. Delirium screening and alerting systems for older hospital inpatients. BMC Health Serv Res. 2025 May 07; 25(1):655. PMID: 40336091; PMCID: PMC12060402.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    25. Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10; 43(20):2285-2295. PMID: 40163793.
      Citations:    
    26. Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla N. Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood Cancer J. 2025 03 26; 15(1):43. PMID: 40140360; PMCID: PMC11947441.
      Citations:    
    27. Churpek MM, Carey KA, Snyder A, Winslow CJ, Gilbert E, Shah NS, Patterson BW, Afshar M, Weiss A, Amin DN, Rhodes DJ, Edelson DP. Multicenter Development and Prospective Validation of eCARTv5: A Gradient-Boosted Machine-Learning Early Warning Score. Crit Care Explor. 2025 Apr 01; 7(4):e1232. PMID: 40138535; PMCID: PMC11949291.
      Citations: 4     Fields:    Translation:Humans
    28. Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):512-519. PMID: 40000354.
      Citations:    
    29. Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Ruiz-Unger J, Shah NS, Mehta M, Cardona OQ, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial. medRxiv. 2025 Jan 14. PMID: 41030935; PMCID: PMC12478340.
      Citations: 1     
    30. Honorato-Mauer J, Shah NN, Maihofer AX, Zai CC, Belangero S, Nievergelt CM, Psychiatric Genomics Consortium for PTSD Ancestry Working Group, Santoro M, Atkinson EG. Characterizing features affecting local ancestry inference performance in admixed populations. Am J Hum Genet. 2025 02 06; 112(2):224-234. PMID: 39753130; PMCID: PMC11866949.
      Citations: 7     Fields:    Translation:Humans
    31. Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 01; 110(1):92-102. PMID: 39363864; PMCID: PMC11694105.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    32. Douville NJ, Bastarache L, He J, Wu KH, Vanderwerff B, Bertucci-Richter E, Hornsby WE, Lewis A, Jewell ES, Kheterpal S, Shah N, Mathis M, Engoren MC, Douville CB, Surakka I, Willer C, Kertai MD. Polygenic Score for the Prediction of Postoperative Nausea and Vomiting: A Retrospective Derivation and Validation Cohort Study. Anesthesiology. 2025 Jan 01; 142(1):52-71. PMID: 39250560; PMCID: PMC11620327.
      Citations: 7     Fields:    Translation:Humans
    33. Urbano-Ispizua ?, Shah NN, Kekre N. Point-of-care CAR T manufacturing solutions: can 1 model fit?all? Blood Adv. 2024 Dec 10; 8(23):6133-6136. PMID: 39265170; PMCID: PMC11707413.
      Citations:    
    34. Kearl TJ, Furqan F, Shah NN. CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. Cancer Metastasis Rev. 2024 Dec 01; 44(1):12. PMID: 39617795.
      Citations:    
    35. Kandula NR, Shah NS, Kumar S, Charley M, Clauson M, Lancki N, Finch EA, Ehrlich-Jones L, Rao G, Spring B, Shah NS, Siddique J. Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial. JAMA Cardiol. 2024 11 01; 9(11):973-981. PMID: 39259546; PMCID: PMC11391361.
      Citations: 5     Fields:    Translation:Humans
    36. Churpek MM, Carey KA, Snyder A, Winslow CJ, Gilbert ER, Shah NS, Patterson BW, Afshar M, Weiss A, Amin DN, Rhodes DJ, Edelson DP. Multicenter Development and Prospective Validation of eCARTv5: A Gradient Boosted Machine Learning Early Warning Score. medRxiv. 2024 Oct 03. PMID: 38562803; PMCID: PMC10984051.
      Citations:    
    37. Buell KG, Carey KA, Dussault N, Parker WF, Dumanian J, Bhavani SV, Gilbert ER, Winslow CJ, Shah NS, Afshar M, Edelson DP, Churpek MM. Development and Validation of a Machine Learning Model for Early Detection of Untreated Infection. Crit Care Explor. 2024 Oct 01; 6(10):e1165. PMID: 39392375; PMCID: PMC11473064.
      Citations:    Fields:    Translation:Humans
    38. Rothman RL, Stewart TG, Mourad A, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Garcia JL, Bramante CT, Shah NS, Singh U, Williamson JC, Rebolledo PA, Jagannathan P, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S, Lindsell CJ, Accelerating COVID-19 Therapeutic Interventions and Vaccines?6 Study Group and Investigators. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 10 01; 7(10):e2439332. PMID: 39422912; PMCID: PMC11581631.
      Citations: 3     Fields:    Translation:HumansCells
    39. Churpek MM, Ingebritsen R, Carey KA, Rao SA, Murnin E, Qyli T, Oguss MK, Picart J, Penumalee L, Follman BD, Nezirova LK, Tully ST, Benjamin C, Nye C, Gilbert ER, Shah NS, Winslow CJ, Afshar M, Edelson DP. Causes, Diagnostic Testing, and Treatments Related to Clinical Deterioration Events Among High-Risk Ward Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1161. PMID: 39356139; PMCID: PMC11446591.
      Citations: 3     Fields:    Translation:Humans
    40. Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair BC, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR, Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386. PMID: 38861666; PMCID: PMC11451378.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    41. Nagaraja Shastri P, Shah N, Lechmann M, Mody H, Retter MW, Zhu M, Li T, Wang J, Shaik N, Zheng X, Ovacik M, Hua F, Jawa V, Boetsch C, Cao Y, Burke J, Datta K, Gadkar K, Upreti V, Betts A. Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy. Clin Pharmacol Ther. 2025 Jan; 117(1):34-55. PMID: 39295563.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    42. Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 12; 30(12):1191.e1-1191.e8. PMID: 39303985; PMCID: PMC12483827.
      Citations:    
    43. Honorato-Mauer J, Shah NN, Maihofer AX, Zai CC, Belangero S, Nievergelt CM, Psychiatric Genomics Consortium for PTSD Ancestry Working Group, Santoro M, Atkinson E. Characterizing features affecting local ancestry inference performance in admixed populations. bioRxiv. 2024 Aug 27. PMID: 39253486; PMCID: PMC11383044.
      Citations:    
    44. Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 08 27; 8(16):4320-4329. PMID: 38889435; PMCID: PMC11372811.
      Citations: 5     Fields:    Translation:Humans
    45. Peloquin S, Cymbalista F, Dreyling M, Shah NN, Murray S, Del Fiacco R, Muehlenbein CE, Lazure P. Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States. BMC Cancer. 2024 Aug 13; 24(1):1003. PMID: 39138575; PMCID: PMC11321192.
      Citations:    
    46. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692. PMID: 39033770.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    47. Govindan S, Spicer A, Bearce M, Schaefer RS, Uhl A, Alterovitz G, Kim MJ, Carey KA, Shah NS, Winslow C, Gilbert E, Stey A, Weiss AM, Amin D, Karway G, Martin J, Edelson DP, Churpek MM. Development and Validation of a Machine Learning COVID-19 Veteran (COVet) Deterioration Risk Score. Crit Care Explor. 2024 Jul 01; 6(7):e1116. PMID: 39028867; PMCID: PMC11262818.
      Citations:    Fields:    Translation:Humans
    48. Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197. PMID: 38824917; PMCID: PMC11617602.
      Citations: 2     Fields:    Translation:Humans
    49. Melody M, Epperla N, Shouse G, Romancik J, Allen P, Moyo TK, Kenkre V, Ollila T, Fitzgerald L, Hess B, David K, Herr MM, Odetola O, Lin A, Moreira J, Ma S, Winter JN, Roy I, Stephens D, Danilov A, Shah NN, Barta SK, Cortese M, Cohen JB, Gordon LI, Karmali R. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 2024 05 28; 8(10):2327-2331. PMID: 38498727; PMCID: PMC11126789.
      Citations: 7     Fields:    Translation:Humans
    50. Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599. PMID: 38531057; PMCID: PMC11145749.
      Citations: 12     Fields:    Translation:Humans
    51. Rothman RL, Stewart TG, Mourad A, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Garcia JL, Bramante CT, Shah NS, Singh U, Williamson JC, Rebolledo PA, Jagannathan P, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S, Lindsell CJ, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial. medRxiv. 2024 May 18. PMID: 38798524; PMCID: PMC11118662.
      Citations:    
    52. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, Thieblemont C, Ursu R, Bartlett NL, Nachar VR, Weiss J, Osterson J, Patel K, Brody JD, Abramson JS, Lunning MA, Shah NN, Ayed A, Kamdar M, Parsons BM, Caimi P, Flynn IW, Herrera AF, Sharman JP, McKenna M, Armand P, Kahl BS, Smith SM, Zelenetz AD, Budde LE, Hutchings M, Phillips TJ, Dickinson M, Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Consensus recommendations on the management of toxicity associated with CD3?CD20 bispecific antibody therapy. Blood. 2024 04 18; 143(16):1565-1575. PMID: 38252906.
      Citations: 62     Fields:    Translation:Humans
    53. Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620. PMID: 38237077; PMCID: PMC10987893.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    54. Furqan F, Shah NN. The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors. Clin Adv Hematol Oncol. 2024 Apr; 22(3):140-147. PMID: 38588273.
      Citations:    Fields:    
    55. Bao X, Kumar SS, Shah NJ, Penning D, Weinstein M, Malhotra G, Rose S, Drover D, Pennington MW, Domino K, Meng L, Treggiari M, Clavijo C, Wagener G, Chitilian H, Maheshwari K, HPI Study Team. AcumenTM hypotension prediction index guidance for prevention and treatment of hypotension in noncardiac surgery: a prospective, single-arm, multicenter trial. Perioper Med (Lond). 2024 Mar 04; 13(1):13. PMID: 38439069; PMCID: PMC10913612.
      Citations: 1     
    56. Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May; 59(5):647-652. PMID: 38361116.
      Citations: 12     Fields:    Translation:Humans
    57. Eakes J, Thomley M, Shah N, Verne S, Messina J, Ambros T, Correa-Selm L. Squamous cell lung carcinoma in a patient with epidermodysplasia verruciformis. JAAD Case Rep. 2024 Aug; 50:108-110. PMID: 39077751; PMCID: PMC11284561.
      Citations:    
    58. Churpek MM, Ingebritsen R, Carey KA, Rao SA, Murnin E, Qyli T, Oguss MK, Picart J, Penumalee L, Follman BD, Nezirova LK, Tully ST, Benjamin C, Nye C, Gilbert ER, Shah NS, Winslow CJ, Afshar M, Edelson DP. Causes, Diagnostic Testing, and Treatments Related to Clinical Deterioration Events among High-Risk Ward Patients. medRxiv. 2024 Feb 06. PMID: 38370788; PMCID: PMC10871454.
      Citations:    
    59. Cashion WT, Zhang X, Puttarajappa C, Sharma A, Mehta R, Ganoza A, Gunabushanam V, Sood P, Wu C, Cherukuri A, Shah N, Kaltenmeier C, Liu H, Dharmayan S, Hariharan S, Molinari M. Interaction between cold ischemia time and Kidney Donor Profile Index on postrenal transplant outcomes. Am J Transplant. 2024 May; 24(5):781-794. PMID: 38307416.
      Citations: 7     Fields:    Translation:Humans
    60. Nasser AAHH, Sidhu M, Prakash R, Mahmood A, PPF Study Collaborative, PPF Study Collaborative, Osman K, Chauhan GS, Nandra R, Dewan V, Davidson J, Al-Azzawi M, Smith C, Gawad M, Palaiologos I, Cuthbert R, Wignadasan W, Banks D, Archer J, Odeh A, Moores T, Tahir M, Brooks M, Biring G, Jordan S, Elahi Z, Shaath M, Veettil M, De C, Handford C, Bansal M, Bawa A, Mattar A, Tandra V, Daadipour A, Taha A, Gangoo S, Srinivasan S, Tarisai M, Budair B, Subbaraman K, Khan F, Gomindes A, Samuel A, Kang N, Kapur K, Mainwaring E, Bridgwater H, Lo A, Ahmed U, Khaleeq T, El-Bakoury A, Rashed R, Hosny H, Yarlagadda R, Keenan J, Hamed A, Riemer B, Qureshi A, Gupta V, Waites M, Bleibleh S, Westacott D, Phillips J, East J, Huntley D, Masud S, Mirza Y, Mishra S, Dunlop D, Khalefa M, Balakumar B, Thibbaiah M, Payton O, Berstock J, Deano K, Sarraf KM, Logishetty K, Lee G, Subbiah-Ponniah H, Shah N, Venkatesan A, Cheseldene-Culley J, Ayathamattam J, Tross S, Randhawa S, Mohammed F, Ali R, Bird J, Khan K, Akhtar MA, Brunt A, Roupakiotis P, Subramanian P, Bua N, Hakimi M, Bitar S, Al Najjar M, Radhakrishnan A, Gamble C, James A, Gilmore C, Dawson D, Sofat R, Antar M, Raghu A, Heaton S, Tawfeek W, Charles C, Burnand H, Duffy S, Taylor L, Magill L, Perry R, Pettitt M, Okoth K, Pinkney T. The characteristics and predictors of mortality in periprosthetic fractures around the knee. Bone Joint J. 2024 Feb 01; 106-B(2):158-165. PMID: 38425310.
      Citations: 2     Fields:    Translation:Humans
    61. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 03; 59(3):373-379. PMID: 38177221.
      Citations: 3     Fields:    Translation:Humans
    62. Burns ML, Hilliard P, Vandervest J, Mentz G, Josifoski A, Varghese J, Fisher C, Kheterpal S, Shah N, Bicket MC. Variation in Intraoperative Opioid Administration by Patient, Clinician, and Hospital Contribution. JAMA Netw Open. 2024 01 02; 7(1):e2351689. PMID: 38227311; PMCID: PMC10792468.
      Citations: 4     Fields:    Translation:Humans
    63. Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 03; 30(3):285-297. PMID: 38142942.
      Citations: 8     Fields:    Translation:HumansCells
    64. Rezazadeh A, Pruett J, Detzner A, Edwin N, Hamadani M, Shah NN, Fenske TS. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):254-259. PMID: 38195321.
      Citations: 3     Fields:    Translation:Humans
    65. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 03; 204(3):887-891. PMID: 38054558.
      Citations:    
    66. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 11 09; 16(1):111. PMID: 37946255; PMCID: PMC10633964.
      Citations:    Fields:    Translation:Humans
    67. Nasser AAHH, Prakash R, Handford C, Osman K, Chauhan GS, Nandra R, Mahmood A, Dewan V, Davidson J, Al-Azzawi M, Smith C, Gawad M, Palaiologos I, Cuthbert R, Wignadasan W, Banks D, Archer J, Odeh A, Moores T, Tahir M, Brooks M, Biring G, Jordan S, Elahi Z, Shaath M, Veettil M, De C, Handford C, Bansal M, Bawa A, Mattar A, Tandra V, Daadipour A, Taha A, Gangoo S, Srinivasan S, Tarisai M, Budair B, Subbaraman K, Khan F, Gomindes A, Samuel A, Kang N, Kapur K, Mainwaring E, Bridgwater H, Lo A, Ahmed U, Khaleeq T, El-Bakoury A, Rashed R, Hosny H, Yarlagadda R, Keenan J, Hamed A, Riemer B, Qureshi A, Gupta V, Waites M, Bleibleh S, Westacott D, Phillips J, East J, Huntley D, Masud S, Mirza Y, Mishra S, Dunlop D, Khalefa M, Balasubramanian B, Thibbaiah M, Payton O, Berstock J, Deano K, Sarraf K, Logishetty K, Lee G, Subbiah-Ponniah H, Shah N, Venkatesan A, Cheseldene-Culley J, Ayathamattam J, Tross S, Randhawa S, Mohammed F, Ali R, Bird J, Khan K, Akhtar MA, Brunt A, Roupakiotis P, Subramanian P, Bua N, Hakimi M, Bitar S, Najjar MA, Radhakrishnan A, Gamble C, James A, Gilmore C, Dawson D, Sofat R, Antar M, Raghu A, Heaton S, Tawfeek W, Charles C, Burnand H, Duffy S, Taylor L, Magill L, Perry R, Pettitt M, Okoth K, Pinkney T. Predictors of mortality in periprosthetic fractures of the hip: Results from the national PPF study. Injury. 2023 Dec; 54(12):111152. PMID: 37939635.
      Citations:    
    68. Kenkel TJ, Sridhar N, Hammons LR, Hintzke M, Shah NN. Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma. Med Sci (Basel). 2023 10 12; 11(4). PMID: 37873752; PMCID: PMC10594436.
      Citations:    
    69. Dickinson MJ, Barba P, J?ger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discov. 2023 09 06; 13(9):1982-1997. PMID: 37249512; PMCID: PMC10481129.
      Citations:    
    70. Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 07 06; 389(1):33-44. PMID: 37407001.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    71. Ragheb J, Norcott A, Benn L, Shah N, McKinney A, Min L, Vlisides PE. Barriers to delirium screening and management during hospital admission: a qualitative analysis of inpatient nursing perspectives. BMC Health Serv Res. 2023 Jun 29; 23(1):712. PMID: 37386400; PMCID: PMC10311863.
      Citations:    
    72. Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023 Jun 27; 7(12):2657-2669. PMID: 36094847; PMCID: PMC10333741.
      Citations:    
    73. Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN. Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. Blood Adv. 2023 06 13; 7(11):2463-2467. PMID: 36417762; PMCID: PMC10241849.
      Citations:    
    74. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654. PMID: 37295445; PMCID: PMC11753452.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    75. Jurczak W, Koh Y, Izutsu K, Tessoulin B, Ma S, Lech-Maranda E, Nagai H, Wang ML, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Gerson JN, Flinn I, Alencar AJ, Lewis D, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 08 20; 41(24):3988-3997. PMID: 37192437; PMCID: PMC10461952.
      Citations: 3     Fields:    Translation:Humans
    76. Henter JI, Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023 07; 29(7):438.e1-438.e16. PMID: 36906275; PMCID: PMC10330221.
      Citations: 6     Fields:    Translation:HumansCells
    77. Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. Haematologica. 2023 02 01; 108(2):588-593. PMID: 36200427; PMCID: PMC9890001.
      Citations:    
    78. Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR. Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. Haematologica. 2023 01 01; 108(1):250-256. PMID: 36106394; PMCID: PMC9827178.
      Citations:    
    79. Sasu BJ, Opiteck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, Hamadani M, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T?cells. Mol Ther. 2023 03 01; 31(3):676-685. PMID: 36518079; PMCID: PMC10014221.
      Citations:    
    80. Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK?inhibitor in BTK?inhibitor?naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18(36):3961-3969. PMID: 36377973.
      Citations:    
    81. Furqan F, Shah NN. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. Annu Rev Med. 2023 01 27; 74:279-291. PMID: 36332638.
      Citations:    
    82. Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022 10 25; 328(16):1595-1603. PMID: 36269852; PMCID: PMC9587497.
      Citations:    
    83. Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 12; 97(12):1580-1588. PMID: 36068950.
      Citations:    
    84. Reamer C, Chi WN, Gordon R, Sarswat N, Gupta C, Gaznabi S, White VanGompel E, Szum I, Morton-Jost M, Vaughn J, Larimer K, Victorson D, Erwin J, Halasyamani L, Solomonides A, Padman R, Shah NS. Continuous Remote Patient Monitoring in Patients With Heart Failure (Cascade Study): Protocol for a Mixed Methods Feasibility Study. JMIR Res Protoc. 2022 Aug 25; 11(8):e36741. PMID: 36006689; PMCID: PMC9459840.
      Citations:    
    85. Winslow CJ, Edelson DP, Churpek MM, Taneja M, Shah NS, Datta A, Wang CH, Ravichandran U, McNulty P, Kharasch M, Halasyamani LK. The Impact of a Machine Learning Early Warning Score on Hospital Mortality: A Multicenter Clinical Intervention Trial. Crit Care Med. 2022 09 01; 50(9):1339-1347. PMID: 35452010.
      Citations:    
    86. Maziarz RT, Diaz A, Miklos DB, Shah NN. Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery. Transplant Cell Ther. 2022 11; 28(11):723-726. PMID: 35940526.
      Citations:    
    87. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):863-868. PMID: 35934632.
      Citations:    
    88. Furqan F, Shah NN. Bispecific CAR T-cells for B-cell Malignancies. Expert Opin Biol Ther. 2022 08; 22(8):1005-1015. PMID: 35653589.
      Citations:    
    89. Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy. 2022 08; 24(8):767-773. PMID: 35597752.
      Citations:    
    90. Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, Sauber G, Yim S, Johnson B, Hari P, Schneider D, Dropulic B, Cusatis RN, Cole SW, Hillard CJ, Shah NN. Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Commun Med (Lond). 2022; 2(1):49. PMID: 35603278; PMCID: PMC9098435.
      Citations:    
    91. Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022 05 01; 8(5):773-775. PMID: 35266965; PMCID: PMC8914887.
      Citations:    
    92. Huang Z, Chavda VP, Vora LK, Gajjar N, Apostolopoulos V, Shah N, Chen ZS. 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Front Pharmacol. 2022; 13:899633. PMID: 35496298; PMCID: PMC9041304.
      Citations:    
    93. Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM. Rap1A, Rap1B, and ?-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. Yale J Biol Med. 2022 03; 95(1):45-56. PMID: 35370486; PMCID: PMC8961707.
      Citations:    
    94. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T?cell, and BiTE recipients. Cancer Cell. 2022 04 11; 40(4):340-342. PMID: 35202585; PMCID: PMC8864440.
      Citations:    
    95. Chi WN, Reamer C, Gordon R, Sarswat N, Gupta C, White VanGompel E, Dayiantis J, Morton-Jost M, Ravichandran U, Larimer K, Victorson D, Erwin J, Halasyamani L, Solomonides A, Padman R, Shah NS. Continuous Remote Patient Monitoring: Evaluation of the Heart Failure Cascade Soft Launch. Appl Clin Inform. 2021 10; 12(5):1161-1173. PMID: 34965606; PMCID: PMC8716190.
      Citations:    
    96. Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021 12 28; 5(24):5626-5630. PMID: 34551065; PMCID: PMC8714710.
      Citations:    
    97. Luo T, Zurko J, Astle J, Shah NN. Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis. Case Rep Hematol. 2021; 2021:9661765. PMID: 34881068; PMCID: PMC8648467.
      Citations:    
    98. Han X, Spicer A, Carey KA, Gilbert ER, Laiteerapong N, Shah NS, Winslow C, Afshar M, Kashiouris MG, Churpek MM. Identifying High-Risk Subphenotypes and Associated Harms From Delayed Antibiotic Orders and Delivery. Crit Care Med. 2021 10 01; 49(10):1694-1705. PMID: 33938715; PMCID: PMC8448901.
      Citations:    
    99. Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN. PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. Haematologica. 2021 10 01; 106(10):2788-2790. PMID: 33853295; PMCID: PMC8485669.
      Citations:    
    100. Palen K, Zurko J, Johnson BD, Hari P, Shah NN. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Cytotherapy. 2021 11; 23(11):985-990. PMID: 34538575.
      Citations:    
    101. Churpek MM, Dumanian J, Dussault N, Bhavani SV, Carey KA, Gilbert ER, Arain E, Ye C, Winslow CJ, Shah NS, Afshar M, Edelson DP. Determining the Electronic Signature of Infection in Electronic Health Record Data. Crit Care Med. 2021 07 01; 49(7):e673-e682. PMID: 33861547; PMCID: PMC8217098.
      Citations:    
    102. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):e775-e781. PMID: 34257042.
      Citations:    
    103. Kabadi AM, Machlin L, Dalal N, Lee RE, McDowell I, Shah NN, Drowley L, Randell SH, Reddy TE. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis. J Cyst Fibros. 2022 Jan; 21(1):164-171. PMID: 34049825; PMCID: PMC8613331.
      Citations:    
    104. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Correction: Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2021 Apr 29; 11(4):82. PMID: 33927193; PMCID: PMC8085088.
      Citations:    
    105. Konchak CW, Krive J, Au L, Chertok D, Dugad P, Granchalek G, Livschiz E, Mandala R, McElvania E, Park C, Robicsek A, Sabatini LM, Shah NS, Kaul K. From Testing to Decision-Making: A Data-Driven Analytics COVID-19 Response. Acad Pathol. 2021 Jan-Dec; 8:23742895211010257. PMID: 33959677; PMCID: PMC8060741.
      Citations:    
    106. Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 03 11; 137(10):1416-1423. PMID: 33120429; PMCID: PMC7955408.
      Citations:    
    107. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M, Ghia P, Le Gouill S. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901. PMID: 33676628; PMCID: PMC11758240.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    108. Shah NN, Hamadani M. Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? J Clin Oncol. 2021 02 10; 39(5):487-498. PMID: 33434076.
      Citations:    
    109. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct; 28(10):717. PMID: 36202527.
      Citations:    
    110. Likosky D, Yule SJ, Mathis MR, Dias RD, Corso JJ, Zhang M, Krein SL, Caldwell MD, Louis N, Janda AM, Shah NJ, Pagani FD, Stakich-Alpirez K, Manojlovich MM. Novel Assessments of Technical and Nontechnical Cardiac Surgery Quality: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2021 Jan 08; 10(1):e22536. PMID: 33416505; PMCID: PMC7822723.
      Citations:    
    111. Fradley MG, Ellenberg K, Alomar M, Swanson J, Kharod A, Nguyen ATH, Khodor S, Mishra S, Duong LM, Shah N, Armanious M, Rhea IB, Schabath MB, Kip KE. Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter. JACC CardioOncol. 2020 Dec; 2(5):747-754. PMID: 34396290; PMCID: PMC8352174.
      Citations:    
    112. Bhavani SV, Lonjers Z, Carey KA, Afshar M, Gilbert ER, Shah NS, Huang ES, Churpek MM. The Development and Validation of a Machine Learning Model to Predict Bacteremia and Fungemia in Hospitalized Patients Using Electronic Health Record Data. Crit Care Med. 2020 11; 48(11):e1020-e1028. PMID: 32796184; PMCID: PMC7554143.
      Citations:    
    113. Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulic B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575. PMID: 33020647.
      Citations:    
    114. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Fo? R, Ghia P, GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479. PMID: 32969597; PMCID: PMC7666748.
      Citations:    
    115. Cronk RJ, Zurko J, Shah NN. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers (Basel). 2020 Sep 05; 12(9). PMID: 32899464; PMCID: PMC7564024.
      Citations:    
    116. Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989. PMID: 32841336; PMCID: PMC7448605.
      Citations:    
    117. Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood Lymphat Cancer. 2020; 10:1-5. PMID: 32943973; PMCID: PMC7473982.
      Citations:    
    118. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 10; 26(10):1876-1885. PMID: 32653622; PMCID: PMC7571859.
      Citations:    
    119. Skepper CK, Armstrong D, Balibar CJ, Bauer D, Bellamacina C, Benton BM, Bussiere D, De Pascale G, De Vicente J, Dean CR, Dhumale B, Fisher LM, Fuller J, Fulsunder M, Holder LM, Hu C, Kantariya B, Lapointe G, Leeds JA, Li X, Lu P, Lvov A, Ma S, Madhavan S, Malekar S, McKenney D, Mergo W, Metzger L, Moser HE, Mutnick D, Noeske J, Osborne C, Patel A, Patel D, Patel T, Prajapati K, Prosen KR, Reck F, Richie DL, Rico A, Sanderson MR, Satasia S, Sawyer WS, Selvarajah J, Shah N, Shanghavi K, Shu W, Thompson KV, Traebert M, Vala A, Vala L, Veselkov DA, Vo J, Wang M, Widya M, Williams SL, Xu Y, Yue Q, Zang R, Zhou B, Rivkin A. Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria. J Med Chem. 2020 07 23; 63(14):7773-7816. PMID: 32634310.
      Citations:    
    120. Hebert C, Gao Y, Rahman P, Dewart C, Lustberg M, Pancholi P, Stevenson K, Shah NS, Hade EM. Prediction of Antibiotic Susceptibility for Urinary Tract Infection in a Hospital Setting. Antimicrob Agents Chemother. 2020 06 23; 64(7). PMID: 32312778; PMCID: PMC7318043.
      Citations:    
    121. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biol Blood Marrow Transplant. 2020 09; 26(9):1670-1678. PMID: 32562858.
      Citations:    
    122. Shah N, Cohen L, Seminario-Vidal L. Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review. J Am Acad Dermatol. 2020 Nov; 83(5):1493-1498. PMID: 32502589.
      Citations:    
    123. Kheterpal S, Vaughn MT, Dubovoy TZ, Shah NJ, Bash LD, Colquhoun DA, Shanks AM, Mathis MR, Soto RG, Bardia A, Bartels K, McCormick PJ, Schonberger RB, Saager L. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. Anesthesiology. 2020 06; 132(6):1371-1381. PMID: 32282427; PMCID: PMC7864000.
      Citations:    
    124. Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 2020 05 26; 4(10):2119-2122. PMID: 32407473; PMCID: PMC7252557.
      Citations:    
    125. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 05 14; 135(20):1739-1749. PMID: 32160294; PMCID: PMC7229262.
      Citations:    
    126. Colquhoun DA, Shanks AM, Kapeles SR, Shah N, Saager L, Vaughn MT, Buehler K, Burns ML, Tremper KK, Freundlich RE, Aziz M, Kheterpal S, Mathis MR. Considerations for Integration of Perioperative Electronic Health Records Across Institutions for Research and Quality Improvement: The Approach Taken by the Multicenter Perioperative Outcomes Group. Anesth Analg. 2020 05; 130(5):1133-1146. PMID: 32287121; PMCID: PMC7663856.
      Citations:    
    127. Kandula NR, Bernard V, Dave S, Ehrlich-Jones L, Counard C, Shah N, Kumar S, Rao G, Ackermann R, Spring B, Siddique J. The South Asian Healthy Lifestyle Intervention (SAHELI) trial: Protocol for a mixed-methods, hybrid effectiveness implementation trial for reducing cardiovascular risk in South Asians in the United States. Contemp Clin Trials. 2020 05; 92:105995. PMID: 32220632; PMCID: PMC8011000.
      Citations:    
    128. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 02 11; 4(3):467-476. PMID: 32027744; PMCID: PMC7013267.
      Citations:    
    129. Badar T, Shah NN. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2020 02 05; 21(2):16. PMID: 32025828.
      Citations:    
    130. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 05; 26(5):893-901. PMID: 31982543.
      Citations:    
    131. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 01 14; 4(1):47-54. PMID: 31899797; PMCID: PMC6960457.
      Citations:    
    132. Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019 12 10; 3(23):4136-4146. PMID: 31821456; PMCID: PMC6963235.
      Citations:    
    133. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 02 10; 38(5):415-422. PMID: 31815579; PMCID: PMC8312030.
      Citations:    
    134. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97. PMID: 31796726; PMCID: PMC6890709.
      Citations:    
    135. Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. Leuk Lymphoma. 2020 04; 61(4):869-874. PMID: 31762357.
      Citations:    
    136. Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 11; 24(11):1488-1495. PMID: 31467178; PMCID: PMC6853108.
      Citations:    
    137. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec; 26(4):210-215. PMID: 31347424.
      Citations:    
    138. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 07 03; 2(7):e196476. PMID: 31276175; PMCID: PMC12124690.
      Citations:    
    139. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019 06 11; 3(11):1661-1669. PMID: 31167818; PMCID: PMC6560348.
      Citations:    
    140. Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270. PMID: 31004001; PMCID: PMC8020996.
      Citations:    
    141. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1689-1694. PMID: 30965140.
      Citations:    
    142. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 07; 25(7):1456-1464. PMID: 30878605.
      Citations:    
    143. Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019; 9:146. PMID: 30915277; PMCID: PMC6423158.
      Citations:    
    144. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6. PMID: 30630534; PMCID: PMC6329157.
      Citations:    
    145. Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 07; 24(7):955-962. PMID: 30568021; PMCID: PMC6656463.
      Citations:    
    146. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 04; 25(4):827-833. PMID: 30572109.
      Citations:    
    147. Fl?isand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zach?e P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. Biol Blood Marrow Transplant. 2019 04; 25(4):720-727. PMID: 30468919.
      Citations:    
    148. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 02; 19(2):95-102. PMID: 30581160.
      Citations:    
    149. Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 2018 12; 20(12):1415-1418. PMID: 30385043.
      Citations:    
    150. Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401. PMID: 30132965; PMCID: PMC7552812.
      Citations:    
    151. Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 01; 25(1):e33-e38. PMID: 30244105.
      Citations:    
    152. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 09; 103(9):1511-1517. PMID: 29880613; PMCID: PMC6119152.
      Citations:    
    153. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 08; 24(8):1610-1614. PMID: 29751116.
      Citations:    
    154. Shah N, Kumar S, Zaman N, Pan CC, Bloodworth JC, Lei W, Streicher JM, Hempel N, Mythreye K, Lee NY. TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth. Nat Commun. 2018 04 27; 9(1):1696. PMID: 29703898; PMCID: PMC5923212.
      Citations:    
    155. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Smith SM, Hamadani M, Bola?os-Meade J, Sureda A. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 04 24; 2(8):933-940. PMID: 29685953; PMCID: PMC5916010.
      Citations: 15     Fields:    Translation:Humans
    156. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 09; 53(9):1210-1213. PMID: 29679076.
      Citations:    
    157. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08; 24(8):1664-1670. PMID: 29680516.
      Citations:    
    158. Shah NN, Fenske TS, Hamadani M, Svoboda J. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et?al. Br J Haematol. 2019 03; 184(5):838-840. PMID: 29528099.
      Citations:    
    159. Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J. Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. Int J Hematol Oncol. 2017 Dec; 6(4):113-121. PMID: 30302232; PMCID: PMC6171986.
      Citations:    
    160. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 04; 103(4):717-727. PMID: 29351985; PMCID: PMC5865423.
      Citations:    
    161. Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018 03; 20(3):394-406. PMID: 29287970.
      Citations:    
    162. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 02; 180(4):534-544. PMID: 29265182.
      Citations:    
    163. Kantak AP, Shah NN. Extensive Surgical Wound Lavage Reduces the Incidence and Severity of Heterotopic Ossification in Primary Total Hip Replacement: A Study of 175 Hip Replacements. Hip Pelvis. 2017 Dec; 29(4):234-239. PMID: 29250497; PMCID: PMC5729165.
      Citations:    
    164. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 01; 24(1):78-85. PMID: 29032272; PMCID: PMC5743624.
      Citations:    
    165. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1955-1960. PMID: 28757436.
      Citations:    
    166. Pan CC, Shah N, Kumar S, Wheeler SE, Cinti J, Hoyt DG, Beattie CE, An M, Mythreye K, Rakotondraibe LH, Lee NY. Angiostatic actions of capsicodendrin through selective inhibition of VEGFR2-mediated AKT signaling and disregulated autophagy. Oncotarget. 2017 Feb 21; 8(8):12675-12685. PMID: 27177332; PMCID: PMC5355044.
      Citations:    
    167. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05; 17(5):305-311.e2. PMID: 28284742.
      Citations:    
    168. Caunca MR, Del Brutto V, Gardener H, Shah N, Dequatre-Ponchelle N, Cheung YK, Elkind MS, Brown TR, Cordonnier C, Sacco RL, Wright CB. Cerebral Microbleeds, Vascular Risk Factors, and Magnetic Resonance Imaging Markers: The Northern Manhattan Study. J Am Heart Assoc. 2016 09 16; 5(9). PMID: 27638784; PMCID: PMC5079015.
      Citations:    
    169. Shah N, Lee NY. Regulation of gene expression and mitochondrial dynamics by SMAD. Mol Cell Oncol. 2016; 3(5):e1204492. PMID: 27857972; PMCID: PMC5068171.
      Citations:    
    170. Kumar S, Pan CC, Shah N, Wheeler SE, Hoyt KR, Hempel N, Mythreye K, Lee NY. Activation of Mitofusin2 by Smad2-RIN1 Complex during Mitochondrial Fusion. Mol Cell. 2016 05 19; 62(4):520-31. PMID: 27184078; PMCID: PMC4877164.
      Citations:    
    171. Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ. Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1251-60. PMID: 26224364.
      Citations: 22     Fields:    Translation:HumansCells
    172. Pan CC, Kumar S, Shah N, Bloodworth JC, Hawinkels LJ, Mythreye K, Hoyt DG, Lee NY. Endoglin Regulation of Smad2 Function Mediates Beclin1 Expression and Endothelial Autophagy. J Biol Chem. 2015 Jun 12; 290(24):14884-92. PMID: 25931117; PMCID: PMC4463436.
      Citations:    
    173. Pan CC, Kumar S, Shah N, Hoyt DG, Hawinkels LJ, Mythreye K, Lee NY. Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis. J Biol Chem. 2014 Sep 12; 289(37):25486-96. PMID: 25070888; PMCID: PMC4162155.
      Citations:    
    174. Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int. 2013 Jun; 26(6):616-22. PMID: 23551167.
      Citations: 13     Fields:    Translation:HumansCells
    Shah's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (484)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _